You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Intelligent and Automatic Image Segmentation Software for High ThroughputAnalysi

    SBC: CytoInformatics LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): It is well established that aging and many chronic diseases, such as cancer and heart failure, are associated with significant losses in skeletal muscle mass and strength in humans. There is agreement across the musclebiology community that important morphological characteristics of muscle fibers, such as fiber area, the number and position of myonuclei, cellul ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. human Microvessel Culture System (hMCS)

    SBC: ANGIOMICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing ev ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Epitaxial GaN on flexible metal tapes for low-cost transistor devices

    SBC: IBEAM MATERIALS, INC.            Topic: 1

    GaN-based devices are the basis of a variety of modern electronics applications, especially in optoelectronics and high-frequency / high-power electronics. These devices are based on epitaxial films grown on single-crystal wafers. The single-crystal wafer substrates are limiting because of their size, expense, mechanical properties and availability. If one could make GaN-based devices over large a ...

    STTR Phase I 2013 Department of EnergyARPA-E
  4. Harvesting specific plant metabolites from hairy root cultures using magnetized n

    SBC: NAPROGENIX, INC.            Topic: NCCIH

    DESCRIPTION: Plants produce a wide variety of valuable bioactive metabolites, but these are commonly present in low concentrations in the wild-type plant. This makes the separation and purification of these compounds complicated and expensive. The applicant company, Naprogenix Inc, has developed a technology for increasing the yields of specific bioactive metabolites in mutant plant cell cultures ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Mitochondrial Uncoupling as a Therapeutic Target in Obesity

    SBC: Nano-Mite Technologies, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Obesity is recognized as a national and global epidemic, as approximately 65% of adults in the United States are classified as overweight or obese as defined by body mass index (BMI). In fact, in the year 2000, the human race reached a historical landmark, when for the first time in history the number of adults with excess weight surpassed the number of those w ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Compounds for the Prevention and Treatment of Rhabdomyolysis

    SBC: Virtual Drug Development Inc.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of lt20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for the 80% of NSCLC patients who present with advanced s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Minimal piggyBac vectors for chromatin integration

    SBC: EXSCIEN CORPORATION            Topic: NIGMS

    In this grant, we describe novel transposon piggyBac vectors engineered to deliver transgenes as efficiently as currently available piggyBac systems, but with significantly less helper DNA co-delivered into the host genome. To generate these plasmids, we first identified an important and previously unreported aspect of transposon biology, that the full-length terminal domains required for successf ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Transdermal H2S Sensing Device for Monitoring Peripheral Artery Disease

    SBC: EXHALIX, LLC            Topic: NHLBI

    Project Summary/Abstract The proposed effort addresses an unmet need for early diagnosis of peripheral artery disease (PAD). PAD is a disorder of vascular circulation that affects more than 8 million Americans, most of whom are unaware of its existence, risks, and threats. PAD is caused primarily by plaque-induced atherosclerosis and in some instances by blood vessel inflammation, stenosis, and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Enhancing mtDNA Repair During Stroke Reperfusion to Reduce Brain Damage

    SBC: EXSCIEN CORPORATION            Topic: NINDS

    DESCRIPTION (provided by applicant): Attempts to develop drug treatments for acute stroke have not fulfilled expectations. Perhaps best illustrating this unsatisfactory situation is the hisory of therapeutic strategies directed at the inhibition of reactive oxygen species (ROS). While decades of laboratory and clinical studies make it clear that ROS are pathogenically important across the entire s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government